Ultime notizie per Premier (NASDAQ:PINC) Azioni

Premier

Premier Inc is a Charlotte, North Carolina-based technology-driven healthcare improvement company, uniting an alliance of United States (U.S.) hospitals, health systems, and other providers and organizations to transform healthcare. The company's revenue is all sourced domestically and is reported in two business segments: the supply chain services and the consulting and technology platform of performance services. It generates the majority of its revenue from the supply chain services segment.

Premier Inc

PREMIER CL A ORD

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.</p>
<p>Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.</p>
<h3 class="wp-block-heading"><strong>Organon &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 6.36%</li>
<li><strong>JP Morgan </strong>analyst Chris Schott downgraded the stock from Neutral to Underweight and raised the price target from $18 to $20 on Sept. 6. This analyst has an accuracy rate of 60%.</li>
<li><strong>Piper Sandler </strong>analyst David Amsellem maintained an Overweight rating and raised the price target from $22 to $24 on April 29. This analyst has an accuracy rate of 68%</li>
<li><strong>Recent News:</strong> Organon will release its third quarter financial results on Oct. 31.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1">atest OGN news</a>.   </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21054143/image-181.png" alt="" class="wp-image-604777" style="width:681px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21054143/image-181.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21054143/image-181-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21054143/image-181-768x717.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Premier, Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 4.15%</li>
<li><strong>Benchmark </strong>analyst Bill Sutherland downgraded the stock from Buy to Hold on Aug. 26. This analyst has an accuracy rate of 64%.</li>
<li><strong>Baird </strong>analyst Eric Coldwell maintained a Neutral rating and cut the price target from $22 to $19 on Aug. 21. This analyst has an accuracy rate of 61%.</li>
<li><strong>Recent News: </strong>Premier will release financial results for its fiscal 2025 first quarter on Tuesday, Nov. 5.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1"> latest PINC news</a>.</li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21050948/image-178.png" alt="" class="wp-image-604724" style="width:700px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21050948/image-178.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21050948/image-178-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21050948/image-178-768x706.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield: </strong>3.97%</li>
<li><strong>Jefferies </strong>analyst Peter Welford maintained a Buy rating and raised the price target from $52.5 to $53 on July 2. This analyst has an accuracy rate of 68%.</li>
<li><strong>Guggenheim </strong>analyst Seamus Fernandez upgraded the stock from Neutral to Buy on March 4. This analyst has an accuracy rate of 62%.</li>
<li><strong>Recent News: </strong>On Oct. 16, the FDA accepted GSK's marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with uncomplicated urinary tract infections (uUTIs).</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1">trend in GSK stock</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="920" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21051023/image-179.png" alt="" class="wp-image-604726" style="width:654px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21051023/image-179.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21051023/image-179-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21051023/image-179-768x711.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure></p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/24/10/41421321/dow-s-p-500-settle-at-record-high-levels-record-6th-consecutive-week-of-gains-fear-index-moves-to-e">Dow, S&amp;P 500 Settle At Record High Levels, Record 6th Consecutive Week Of Gains: Fear Index Moves To &#8216;Extreme Greed&#8217; Zone</a></strong></li>
</ul>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>


News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

PINC

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

<p>Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $19.25, a high estimate of $20.00, and a low estimate of $19.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.33%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727884883_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Premier by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Premier. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Premier compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Premier's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Premier's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PINC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Premier analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Premier</h2>
<p>Premier Inc is a Charlotte, North Carolina-based technology-driven healthcare improvement company, uniting an alliance of United States (U.S.) hospitals, health systems, and other providers and organizations to transform healthcare. The company's revenue is all sourced domestically and is reported in two business segments: the supply chain services and the consulting and technology platform of performance services. It generates the majority of its revenue from the supply chain services segment.</p>
<h3>Breaking Down Premier's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Premier displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>2.91%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Premier's net margin is impressive, surpassing industry averages. With a net margin of <strong>17.32%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Premier's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.12%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Premier's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.79%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Premier's debt-to-equity ratio is below the industry average. With a ratio of <b>0.06</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Premier: Insights From 4 Financial Analysts

<p>Canaccord Genuity  analyst Richard Close   maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Hold and lowers the price target from $20 to $19.</p>


Canaccord Genuity Maintains Hold on Premier, Lowers Price Target to $19

<p><a href="https://premierinc.com/newsroom/press-releases/premier-inc-and-long-grove-pharmaceuticals-join-forces-to-increase-supply-of-norepinephrine-iv-bags" title="https://premierinc.com/newsroom/press-releases/premier-inc-and-long-grove-pharmaceuticals-join-forces-to-increase-supply-of-norepinephrine-iv-bags">https://premierinc.com/newsroom/press-releases/premier-inc-and-long-grove-pharmaceuticals-join-forces-to-increase-supply-of-norepinephrine-iv-bags</a></p>


Premier And Long Grove Pharmaceuticals Partner To Increase Supply Of Norepinephrine IV Bags, Addressing Ongoing Shortages And Ensuring Long-Term Availability For Critical Care

<p>Pursuant to the partnership agreement, Premier exchanged all its holdings in the S2S Global business, its direct sourcing subsidiary, for a&nbsp;20 percent&nbsp;minority interest in Prestige.</p>
<p>This new ownership interest is in addition to an existing indirect investment that Premier made in the company in 2020, increasing Premier&#39;s total ownership (direct and indirect) interest in Prestige to approximately&nbsp;24.2 percent&nbsp;in the aggregate.</p>
<p>&nbsp;</p>


Asset Sales

Premier, Inc. Enters Partnership With Prestige Ameritech; Divests Ownership Position In S2S Global

<p>JP Morgan  analyst Anne Samuel   maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Neutral and lowers the price target from $21 to $19.</p>


JP Morgan Maintains Neutral on Premier, Lowers Price Target to $19

<p>Benchmark  analyst Bill Sutherland   downgrades Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) from Buy to Hold.</p>


Downgrades

Benchmark Downgrades Premier to Hold

<p>Canaccord Genuity  analyst Richard Close   maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Hold and lowers the price target from $21 to $20.</p>


Canaccord Genuity Maintains Hold on Premier, Lowers Price Target to $20

<p>Baird  analyst Eric Coldwell   maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Neutral and lowers the price target from $22 to $19.</p>


Baird Maintains Neutral on Premier, Lowers Price Target to $19

<p>Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.49 by 40.82 percent. This is a 2.99 percent increase over earnings of $0.67 per share from the same period last year.  The company reported quarterly sales of $350.27 million which beat the analyst consensus estimate of $313.21 million by 11.83 percent.  This is a 2.91 percent increase over sales of $340.36 million the same period last year.</p>


Earnings

Earnings Beats

Premier Q4 Adj $0.69 Beats $0.49 Estimate, Sales $350.27M Beat $313.21M Estimate

<p>Coleman will succeed Craig McKasson, who will retire on December 31, 2024, and will serve as a strategic advisor to the company through 2026.</p>


Management

Premier, Inc. Names Glenn Coleman As The Chief Administrative And Financial Officer, Effective November 11, 2024

<ul>
<li><i>Partnership to support more than $3.5 billion in AllSpire annual GPO purchasing volume.</i></li>
<li><i>Premier supply chain services and performance improvement technology to enable operational efficiency, supply chain innovation and value​ for AllSpire members.</i></li>
</ul>


Contracts

AllSpire Health Partners Selects Premier As National GPO

<p>Teleflex Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), a leading global provider of medical technologies, today announced it was awarded two group purchasing agreements with Premier, Inc. Effective July 1, 2024, the Premier National Hemostasis Products and SURPASS&reg; Hemostasis Products agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex products within the hemostatic portfolio.<br />
&nbsp;</p>
<p>Premier&#39;s SURPASS&reg; program is designed to drive the highest-level commitment and savings for members through aggregated purchasing of high-quality products and services. The program brings together Premier&#39;s most committed members to coordinate purchasing decisions and maintain standardization across their facilities. By providing additional value to Premier contracted suppliers through volume and commitment, the program is expected to achieve best-in-market pricing.</p>
<p>QuikClot&trade; Hemostatic Dressings and Devices control bleeding faster than standard gauze or laparotomy pads,1-3&nbsp;enabling clinicians to move patients to the next stage of care quickly. The portfolio includes a range of products to support clinicians throughout the hospital, including in the Emergency Department, Operating Room, Intensive Care Unit, and Catheterization Lab.</p>


Teleflex Secures Premier Agreements for Hemostasis Products with Special Pricing

<p>Analysts' ratings for Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $21.5, a high estimate of $22.00, and a low estimate of $21.00. Experiencing a 13.13% decline, the current average is now lower than the previous average price target of $24.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1716922860_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Premier among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$21.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Premier. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Premier compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Premier's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Premier's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PINC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Premier analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Premier Better</h2>
<p>Premier Inc is a Charlotte, North Carolina-based national group purchasing organization providing primary supply chain services to large hospital systems and more recently to alternate outpatient locations as it expands its footprint. Through acquisitions, the company also offers a compliment of advisory services and consulting services along with software-as-a-service-based subscriptions. The company's revenue is all sourced domestically and is reported in two business segments: the core supply chain services (approximately 70% of fiscal 2019 revenue) and the consulting and technology platform of performance services (approximately 30%).</p>
<h3>Key Indicators: Premier's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Premier showcased positive performance, achieving a revenue growth rate of <strong>6.32%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Premier's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-11.73%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Premier's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-1.86%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-1.12%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.07</strong>, Premier adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 4 Analyst Evaluations For Premier

<p>JP Morgan  analyst Anne Samuel   maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Neutral and lowers the price target from $23 to $21.</p>


JP Morgan Maintains Neutral on Premier, Lowers Price Target to $21

<p>In the preceding three months, 4 analysts have released ratings for Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Premier and provided 12-month price targets. The average target is $21.88, accompanied by a high estimate of $22.50 and a low estimate of $21.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 13.62%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715187623_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Premier by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$21.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$22.50</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Premier. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Premier compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Premier's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Premier's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PINC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Premier analyst ratings.</strong></a></p>
<h2>Get to Know Premier Better</h2>
<p>Premier Inc is a Charlotte, North Carolina-based national group purchasing organization providing primary supply chain services to large hospital systems and more recently to alternate outpatient locations as it expands its footprint. Through acquisitions, the company also offers a compliment of advisory services and consulting services along with software-as-a-service-based subscriptions. The company's revenue is all sourced domestically and is reported in two business segments: the core supply chain services (approximately 70% of fiscal 2019 revenue) and the consulting and technology platform of performance services (approximately 30%).</p>
<h3>Premier: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Premier's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-6.92%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Premier's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>16.22%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Premier's ROE excels beyond industry benchmarks, reaching <strong>2.29%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Premier's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.41%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Premier's debt-to-equity ratio is below the industry average. With a ratio of <b>0.07</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Unveiling 4 Analyst Insights On Premier

<p>Piper Sandler  analyst Jessica Tassan   maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Neutral and lowers the price target from $24 to $22.</p>


Piper Sandler Maintains Neutral on Premier, Lowers Price Target to $22

<p>Canaccord Genuity  analyst Richard Close   downgrades Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) from Buy to Hold and lowers the price target from $27 to $21.</p>


Canaccord Genuity Downgrades Premier to Hold, Lowers Price Target to $21

<p>Baird  analyst Eric Coldwell   maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Neutral and lowers the price target from $25 to $22.</p>


Baird Maintains Neutral on Premier, Lowers Price Target to $22

Guidance

Premier Sees FY24 Total Net Revenue Of $1.265B-$1.325B Vs. $1.3B estimate; Maintains Adjusted EPS Outlook Of $2.06-$2.18 Vs. $2.15 Estimate

Leerink Partners analyst Michael Cherny maintained a Hold rating on Premier (PINC – Research Report) on August 20 and set a price target of $20.00....

Premier Inc.: Balancing Restructuring Challenges with Positive Performance Services Uptake

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD – Research Report) and Premi...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD) and Premier (PINC)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Premier</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pinc-stock-quote/"><strong>PINC</strong></a></span>) just reported results for the fourth quarter of 2024.</p><ul><li>Premier reported earnings per share of 69 cents. This was above the analyst estimate for EPS of 49 cents.</li><li>The company reported revenue of $350.27 million.</li><li>This was 11.83% better than the analyst estimate for revenue of $313.21 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div>	<p>The post <a href="https://investorplace.com/earning-results/2024/08/pinc-stock-earnings-premier-for-q4-of-2024/">PINC Stock Earnings: Premier Beats EPS, Beats Revenue for Q4 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

PINC Stock Earnings: Premier Beats EPS, Beats Revenue for Q4 2024

Premier Inc rating downgraded on FY25-26 guidance miss at Benchmark

These stocks are expected to benefit from the reshoring trend currently happening

Premier divests ownership position in S2S Global via new partnership with Prestige Ameritech

Barclays analyst Stephanie Davis assigned a Hold rating to Premier (PINC – Research Report) today and set a price target of $20.00. The company's s...

Premier (PINC) Receives a Hold from Barclays

Eric Coldwell, an analyst from Robert W. Baird, reiterated the Hold rating on Premier (PINC – Research Report). The associated price target remains...

Premier Inc.: Balancing Strategic Growth and Headwinds in Financial Outlook – Hold Rating Justified

Premier ( ($PINC) ) has provided an update. Premier, Inc.'s 2024 Sustainability Report highlights its commitment to environmental stewardship, soci...

Premier Highlights 2024 Commitment to Sustainability and ESG

Premier declares $0.21 dividend

CAMT

FLEX

GILD

NVMI

RSHO

STAG

STLD

Press Releases

Premier, Inc. to Participate in BofA Securities Healthcare Conference on May 14, 2024

Premier's PINC AI™ and Fortune Name the Nation's 15 Top Health Systems™

Premier, Inc. to Report Fiscal 2024 Fourth-Quarter and Full-Year Results and Host Conference Call on August 20, 2024

Premier, Inc. Declares Quarterly Cash Dividend

AllSpire Health Partners Selects Premier, Inc. as its National GPO

Premier, Inc. Reports Fiscal-Year 2024 Fourth-Quarter and Full-Year Results

Premier, Inc. Appoints Glenn Coleman as Chief Administrative and Financial Officer

Premier, Inc. Divests Ownership Position in S2S Global Through New Partnership With Prestige Ameritech

Premier, Inc. to Report Fiscal 2025 First-Quarter Results and Host Conference Call on November 5, 2024

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Premier

Notizie

Ultime notizie per Premier (NASDAQ:PINC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO